VFA
ADMS

Virtus Fund Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

Virtus Fund Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-249
Closed -$5K – 2151
2014
Q2 		$5K Buy
+249
New +$4.46K ﹤0.01% 2830

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
BS
Bow Street New York $52.4M AUM 2.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Virtus Fund Advisers's ADMS Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q3 2014, closing a stake of 249 shares — an estimated $5K sold.

Virtus Fund Advisers first reported a position in ADMS in Q2 2014 and held it in 1 quarter. The position peaked at $5K in Q2 2014. 44 funds tracked by Wall St. Rank hold ADMS as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Adamas Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 249 Adamas Pharmaceuticals shares in Q3 2014, an estimated $5K.
  • Virtus Fund Advisers first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Adamas Pharmaceuticals position peaked at $5K in Q2 2014.
  • 44 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.